CA15-3 ELISA Kit

Sample

Serum or plasma

Species Reactivity

Human

Detection Method

sELISA

Intended Use

The CA15-3 ELISA Kit is intended for the quantitative determination of the cancer antigen CA15-3 concentration in human serum or plasma.

Contents of Kit

1. Microwells coated with streptavidin: 12×8×1
2. Anti CA15-3-Biotin Conjugate: 1 bottle (Ready to use) 12 ml
3. Anti CA15-3-HRP Enzyme Conjugate: 1 bottle (Ready to use) 12 ml
4. Sample Diluent: 1 bottle (Ready to use) 25 ml
5. CA 15-3 Standards: 6 vials (Ready to use) 0.5 ml
6. TMB Solution: 1 bottle (Ready to use) 12 ml
7. Stop Solution: 1 bottle (Ready to use) 12 ml
8. Wash Concentrate 20×: 1 Bottle 25 ml

Storage

1. Store the kit at 2-8°C.
2. Keep microwells sealed in a dry bag with desicants.
3. The reagents are stable until expiration of the kit.
4. Do not expose test reagents to heat, sun or strong light.

General Description

Breast cancer is the most common life-threatening malignant lesion in women of developed countries today, with approximately 180,000 new cases diagnosed every year. Roughly half of these newly diagnosed patients are node-negative, however 30% of these cases progress to metastatic disease. There are a number of tumor markers that can help clinicians to identify and diagnose which breast cancer patients will have a more aggressive disease. These markers include estrogen and progesterone receptors, DNA ploidy and percent-S phase profile, epidermal growth factor receptor, HER-2/neu oncogene, p53 tumor suppressor gene, cathepsin D, proliferation markers and CA15-3. CA15-3 is most useful for monitoring patients post-operatively for recurrence, particularly in metastatic disease cases. 96% of patients with local and systemic recurrence have elevated CA15-3, which can be used to predict recurrence earlier than radiological and clinical criteria. A 25% increase in the serum CA15-3 is associated with progression of carcinoma. A 50% decrease in serum CA15-3 is associated with response to treatment. CA15-3 is more sensitive than CEA in early detection of breast cancer recurrence. In combination with CA125, CA15-3 has been shown to be useful in early detection of relapse of ovarian cancer. CA15-3 levels are also increased in colon, lung and hepatic tumors.

Standard Curve

Results of a typical standard run with optical density readings at 450nm shown in the Y-axis against CA15-3 concentrations shown in the X axis. This standard curve is for the purpose of illustration only, and should not be used to calculate unknowns. Each user should obtain his or her own data and standard curve for every test run.